Patients with advanced ovarian cancer have used their medication for more than 30 weeks with significant results
$Allarity Therapeutics(ALLR.US$ On June 25, 2024, the clinical-stage biopharmaceutical company Allarity Therapeutics announced that the drug stenoparib, which treats the inverted symptoms of sterile ovarian cancer by Evans Holdings, has made significant progress in its phase II clinical trial. The trial showed that several patients had been treated for more than 30 weeks, indicating that the drug had long-term clinical benefits. This was a further announcement following an earlier statement in May 2024 showing that stenoparib had significant tumor shrinkage and long-term disease stability in heavily pretreated patients. The company has decided to discontinue patient recruitment and focus on a follow-up trial aimed at speeding up stenoparib's passage through regulatory approval. The trial's lead researcher Kathryn N. Moore, MD, emphasized the need to continue developing next-generation PARP inhibitors like stenoparib. CEO Thomas Jensen emphasized the drug's good safety and its potential as a next-generation treatment option. The company plans to present detailed test data at high-level scientific meetings, adhering to the usual rules for such events. The PARP inhibitor market is expected to reach $22 billion in 2028, and there is great interest in drugs with better tolerability and safety. Due to its dual inhibitory activity and safety, which can also inhibit Tankyrase 1 and 2, stenoparib is considered a different therapeutic product. Allarity Therapeutics uses its proprietary DRP® companion diagnostic method to select patients who may benefit from stenoparib, which has been shown to make a difference in increasing treatment efficacy rates.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
